Wave Life Sciences, Inc. — Form SCHEDULE 13D/A
Filed August 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 32/100
What the filing says
RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah executed a Joint Filing Agreement dated August 11, 2026, to file a single Schedule 13D/13G statement regarding their beneficial ownership of Wave Life Sciences common stock. The agreement allows these parties to file coordinated disclosures and may be terminated by any filer with one week's written notice. The filing does not disclose specific shareholding percentages, dollar amounts, or share counts.
Why this rating
Procedural filing coordination agreement; no disclosed stake size, acquisition, or business change. Routine beneficial ownership disclosure mechanism.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.